(Q35194544)

7 August 2017

1 reference

title

The gastrointestinal tolerability and safety of oral bisphosphonates (English)

1 reference

7 August 2017

John K Marshall

1

1 reference

PubMed ID

12904162

7 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Expert Opinion on Drug Safety

7 August 2017

1 reference

7 August 2017

1

1 reference

7 August 2017

1

1 reference

7 August 2017

71-78

1 reference

The therapeutic use of bisphosphonates

7 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Treatment of osteoporosis with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

The effect of dosing regimen on the pharmacokinetics of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Fatal esophageal perforation with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Incidence of adverse oesophageal and gastric events in alendronate users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Incidence of gastrointestinal side effects due to alendronate is high in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Upper gastrointestinal adverse events and cyclical etidronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Alendronate and naproxen are synergistic for development of gastric ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Nonclinical model for assessing gastric effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.1.71

21 January 2018

Identifiers

DOI

10.1517/14740338.1.1.71

1 reference

7 August 2017

1 reference

PubMed ID

12904162